Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142074 | 1.00 | CCR2 (0.35) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL26317203 | 0.98 | CCR2 (0.34) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL24736818 | 0.98 | CCR2 (0.34) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL22023694 | 0.97 | HTR2A (0.33) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL18459246 | 0.95 | HTR2A (0.32) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL21191726 | 0.93 | HTR2A (0.34) | HTR2A | |
| SCHEMBL22024142 | 0.90 | HTR2A (0.33) | HTR2A | |
| SCHEMBL26653352 | 0.89 | GNAO1 (0.40) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL23896488 | 0.89 | GNAO1 (0.40) | CCR2CCR1CCR5CXCR4GNAO1 | |
| SCHEMBL22023796 | 0.88 | GNAO1 (0.39) | CCR2CCR1CCR5CXCR4GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | CCR2 1178/4885CCR1 3737/4885CCR5 1495/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | CCR2 1178/4885CCR1 3737/4885CCR5 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.